ERBB1/EGFR and ERBB2 (HER2/neu) - Targeted therapies in cancer and cardiovascular system with cardiovascular drugs

International Journal of Cardiology

Volumn 176, Issue 3, 2014, Pages 1301-1303

  Patanè, Salvatore ^a  

^a Cardiologia Ospedale San Vincenzo   (Italy)

Author keywords

Cardio oncology; Cardiotoxicity; EGFR; ERBB1; ERBB2; Her2 neu

Indexed keywords

CARDIOVASCULAR AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ANIMAL; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; NEOPLASMS; TRENDS;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84908252187     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.07.161     Document Type: Article

References (78)

1. E. Conti, A. Romiti, and M.B. Musumeci Arterial thrombotic events and acute coronary syndromes with cancer drugs: are growth factors the missed link?: what both cardiologist and oncologist should know about novel angiogenesis inhibitors Int J Cardiol 167 6 Sep 10 2013 2421 2429
2. S. Rateesh, S.A. Luis, C.R. Luis, B. Hughes, and M. Nicolae Myocardial infarction secondary to 5-fluorouracil: not an absolute contraindication to rechallenge? Int J Cardiol 172 2 Mar 15 2014 e331 e333
3. S. Kurisu, T. Iwasaki, K. Ishibashi, N. Mitsuba, Y. Dohi, and Y. Kihara Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients Int J Cardiol 167 5 Sep 1 2013 2335 2337
4. J.M. Scott, L.W. Jones, and W.E. Hornsby Cancer therapy-induced autonomic dysfunction in early breast cancer: implications for aerobic exercise training Int J Cardiol 171 2 Feb 1 2014 e50 e51
5. S. Claridge, A. Chakrabarti, K. Greaves, and C.J. Boos Successful use of trastuzumab following cardiac resynchronisation therapy Int J Cardiol 166 2 Jun 20 2013 e33 e34
6. M. Lotrionte, G. Palazzoni, and A. Abbate Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study Int J Cardiol 167 3 Aug 10 2013 1055 1057
7. M.G. Kaya, M. Ozkan, and O. Gunebakmaz Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study Int J Cardiol 167 5 Sep 1 2013 2306 2310
8. K.L. Wang, C.J. Liu, and T.F. Chao Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis Int J Cardiol 167 5 Sep 1 2013 2162 2166
9. Y.F. Hu, C.J. Liu, and P.M. Chang Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients Int J Cardiol 165 2 May 10 2013 355 357
10. A. Budaj-Fidecka, M. Kurzyna, and A. Fijałkowska ZATPOL registry investigators. In-hospital major bleeding predicts mortality in patients with pulmonary embolism: an analysis of ZATPOL registry data Int J Cardiol 168 4 Oct 9 2013 3543 3549
11. P. Pugliatti, R. Donato, G. Di Bella, S. Carerj, and S. Patanè Contrast-enhancing right atrial thrombus in cancer patient Int J Cardiol 173 3 May 15 2014 e35 e37
12. S. Grover, D.P. Leong, and A. Chakrabarty Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers Int J Cardiol 168 6 Oct 15 2013 5465 5467
13. W. Jurczak, S. Szmit, and M. Sobociński Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study Int J Cardiol 168 6 Oct 15 2013 5212 5217
14. C. Lestuzzi Cardioncology, oncocardiology. Are we barking up the wrong tree? Int J Cardiol 167 2 Jul 31 2013 307 309
15. R. Pugliatti, R. Donato, C. Zito, S. Carerj, and S. Patanè Cardio inhibitory vasovagal syncope in a cancer patient Int J Cardiol 174 2 Jun 15 2014 e64 e65
16. P. Pugliatti, C. De Gregorio, and S. Patanè The chance finding of echocardiographic complications of infective endocarditis Int J Cardiol 161 3 Nov 29 2012 e50 e51
17. S. Patanè HERG-Targeted therapy in both cancer and cardiovascular system with cardiovascular drugs Int J Cardiol 176 3 Aug 2 2014 1082 1085
18. Y. Elkina, S. Palus, and A. Tschirner Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia Int J Cardiol 170 2 Dec 10 2013 160 166
19. J. Springer, A. Tschirner, K. Hartman, S. von Haehling, S.D. Anker, and W. Doehner The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy Int J Cardiol 168 4 Oct 9 2013 3527 3531
20. S. Palus, S. von Haehling, and V.C. Flach Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia Int J Cardiol 168 4 Oct 9 2013 3412 3418
21. V. Avbelj, and R. Trobec A closer look at electrocardiographic P waves before and during spontaneous cardioinhibitory syncope Int J Cardiol 166 3 Jul 1 2013 e59 e61
22. W.J. Jang, H.R. Yim, S.H. Lee, S.J. Park, J.S. Kim, and Y.K. On Prognosis after tilt training in patients with recurrent vasovagal syncope Int J Cardiol 168 4 Oct 9 2013 4264 4265
23. K.P. Loh, and O. Ogunneye Malignant cardioinhibitory vasovagal syncope - an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! Int. J Cardiol 164 3 Apr 15 2013 e38 e39
24. S. Patanè, and F. Marte Prostate-specific antigen kallikrein: from prostate cancer to cardiovascular system Eur Heart J 30 10 May 2009 1169 1170
25. M. Arcopinto, C.A. Cella, and R. Wesolowski Primary prevention of cancer-related thrombosis: special focus on ambulatory patients Int J Cardiol 173 3 May 15 2014 583 584
26. S. Patanè Breast cancer treatment cardioprotective strategies: the King is naked J Am Heart Assoc 2014 Published July 22 2014 http://www.jaha.ahajournals.org/content/3/2/e000665/reply
27. D. Cardinale A new frontier: cardio-oncology Cardiologia 41 9 Sep 1996 887 891
28. S. Patanè, and F. Marte Prostate-specific antigen kallikrein and acute myocardial infarction: where we are where are we going? Int J Cardiol 146 1 Jan 7 2011 e20 e22
29. S. Patanè, and F. Marte Prostate-specific antigen and acute myocardial infarction: a possible new intriguing scenario Int J Cardiol 134 3 May 29 2009 e147 e149
30. S. Patanè Prostate-specific antigen kallikrein and the heart World J Cardiol 1 1 Dec 31 2009 23 25
31. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing urological procedures? J Cardiovasc Transl Res 7 3 Apr 2014 369 371
32. S. Patanè Is there a need for bacterial endocarditis prophylaxis in patients undergoing gastrointestinal endoscopy? J Cardiovasc Transl Res 7 3 Apr 2014 372 374
33. M. Scarano, F. Pezzuoli, G. Torrisi, G.M. Calvagna, and S. Patanè Cardiovascular implantable electronic device infective endocarditis Int J Cardiol 173 3 May 15 2014 e38 e39
34. S. Patanè Cardiotoxicity: cisplatin and long term cancer survivors Int J Cardiol 175 1 Jul 15 2014 201 202
35. S. Patanè A challenge in cardiology: the oncosurgery Int J Cardiol 174 2 Jul 15 2014 411 412
36. S. Patanè Insights into cardio-oncology: adrenergic receptor signaling and pathways in breast cancer Curr Med Res Opin Jun 26 2014 1 2 http://informahealth.com
37. S. Patanè, F. Marte, M. Sturiale, and G. Dattilo ST-segment elevation and diminution of prostate-specific antigen in a patient with coronary spasm and without significant coronary stenoses Int J Cardiol 148 2 Apr 14 2011 e31 e33
38. Y. Ozkanlar, M.S. Aktas, and M. Turkeli Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity Int J Cardiol 173 3 May 15 2014 519 521
39. S. Patanè Heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies J Card Fail 20 6 Jun 2014 456 457
40. S. Patanè Cardiotoxicity: Anthracyclines and long term cancer survivors Int J Cardiol 176 3 2014 1326 1328
41. S. Patanè A dark side of the cardio-oncology: the bacterial endocarditis prophylaxis Int J Cardiol 157 3 Jun 14 2012 448 449
42. Y. Liao, J. Bin, and T. Luo CB1 cannabinoid receptor deficiency promotes cardiac remodeling induced by pressure overload in mice Int J Cardiol 167 5 Sep 1 2013 1936 1944
43. M. Shi, M. Zhao, and M. Hu β2-AR-induced Her2 transactivation mediated by Erbin confers protection from apoptosis in cardiomyocytes Int J Cardiol 167 4 Aug 20 2013 1570 1577
44. N. Makki, K.W. Thiel, and F.J. Miller Jr. The epidermal growth factor receptor and its ligands in cardiovascular disease Int J Mol Sci 14 10 Oct 15 2013 20597 20613 [Review]
45. A. Mahipal, N. Kothari, and S. Gupta Epidermal growth factor receptor inhibitors: coming of age Cancer Control 21 1 Jan 2014 74 79
46. N. Ulu, G.M. Mulder, and P. Vavrinec Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats J Pharmacol Exp Ther 345 3 Jun 2013 393 403
47. M.E. Irwin, K.L. Mueller, N. Bohin, Y. Ge, and J.L. Boerner Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib J Cell Physiol 226 9 Sep 2011 2316 2328
48. J. Bilbro, M. Mart, and N. Kyprianou Therapeutic value of quinazoline-based compounds in prostate cancer Anticancer Res 33 11 Nov 2013 4695 4700
49. I. Staudacher, J. Jehle, and K. Staudacher HERG K + channel-dependent apoptosis and cell cycle arrest in human glioblastoma cells PLoS One 9 2 Feb 6 2014 e88164
50. H. Hui, M.A. Fernando, and A.P. Heaney The alpha1-adrenergic receptor antagonist doxazosin inhibits EGFR and NF-kappaB signalling to induce breast cancer cell apoptosis Eur J Cancer 44 1 Jan 2008 160 166
51. C. Alberti Apoptosis induction by quinazoline-derived alpha1-blockers in prostate cancer cells: biomolecular implications and clinical relevance Eur Rev Med Pharmacol Sci 11 1 Jan-Feb 2007 59 64
52. C. Han, W.C. Bowen, G.K. Michalopoulos, and T. Wu Alpha-1 adrenergic receptor transactivates signal transducer and activator of transcription-3 (Stat3) through activation of Src and epidermal growth factor receptor (EGFR) in hepatocytes J Cell Physiol 216 2 Aug 2008 486 497
53. C. Zhang, F. Lv, L. Zhou, X. Li, X.X. Wu, and R.M. Hoffman Effect of verapamil on the expression of EGFR and NM23 in A549 human lung cancer cells Anticancer Res 29 1 Jan 2009 27 32
54. Z.S. Zhong, L.F. Wu, Y.H. Zheng, and L. Fang Experimental study of c-erbB2 on the fertilization in mouse Zhongguo Ying Yong Sheng Li Xue Za Zhi 19 1 Feb 2003 60 64 [Chinese]
55. X. Jin, L. Fang, Y.H. Zheng, Z.S. Zhong, and H.B. Kuang Effects of c-erbB(2) on the hCG-induced progesterone production of rat luteal cells Sheng Li Xue Bao 52 1 Feb 2000 17 21
56. K.J. Cho, M.M. Hill, S. Chigurupati, G. Du, R.G. Parton, and J.F. Hancock Therapeutic levels of the hydroxmethylglutaryl-coenzyme A reductase inhibitor lovastatin activate ras signaling via phospholipase D2 Mol Cell Biol 31 6 Mar 2011 1110 1120
57. T.T. Zhao, D. Trinh, C.L. Addison, and J. Dimitroulakos Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors PLoS One 5 9 Sep 3 2010 e12563
58. T. Kusama, M. Mukai, and T. Iwasaki Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors Cancer Res 61 12 Jun 15 2001 4885 4891
59. T. Kusama, M. Mukai, and T. Iwasaki 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis Gastroenterology 122 2 Feb 2002 308 317
60. G. Herrero-Martin, and A. López-Rivas Statins activate a mitochondria-operated pathway of apoptosis in breast tumor cells by a mechanism regulated by ErbB2 and dependent on the prenylation of proteins FEBS Lett 582 17 Jul 23 2008 2589 2594
61. L. Ma, N. Niknejad, I. Gorn-Hondermann, K. Dayekh, and J. Dimitroulakos Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells PLoS One 7 9 2012 e46055
62. C. Cemeus, T.T. Zhao, G.M. Barrett, I.A. Lorimer, and J. Dimitroulakos Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status J Neurooncol 90 1 Oct 2008 9 17
63. B.B. Knight, G.M. Oprea-Ilies, and A. Nagalingam Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells Endocr Relat Cancer 18 4 Jul 1 2011 413 428
64. A.J. Mantha, J.E. Hanson, G. Goss, A.E. Lagarde, I.A. Lorimer, and J. Dimitroulakos Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor Clin Cancer Res 11 6 Mar 15 2005 2398 2407
65. M. Veeraputhiran, and M. Sundermeyer Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin Clin Lung Cancer 9 4 Jul 2008 232 234
66. J. Dimitroulakos, I.A. Lorimer, and G. Goss Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway Clin Cancer Res 12 14 Pt 2 Jul 15 2006 4426s 4431s
67. K.E. Hwang, S.J. Kwon, and Y.S. Kim Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR Exp Cell Res 323 2 May 1 2014 288 296
68. Y. Liao, H. Zhao, and A. Ogai Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation Hypertens Res 31 2 Feb 2008 335 344
69. C. Riganti, H. Pinto, and E. Bolli Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer Biochem Pharmacol 82 9 Nov 1 2011 1079 1089
70. P. Kometiani, L. Liu, and A. Askari Digitalis-induced signaling by Na +/K + -ATPase in human breast cancer cells Mol Pharmacol 67 3 Mar 2005 929 936
71. K.M. Kim, and Y.J. Lee Role of HER-2/neu signaling in sensitivity to tumor necrosis factor-related apoptosis-inducing ligand: enhancement of TRAIL-mediated apoptosis by amiloride J Cell Biochem 96 2 Oct 1 2005 376 389
72. M. Sakaguchi, Y. Kuroda, and M. Hirose The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor Anesth Analg 102 Apr 2006
73. C. Grossmann, A.W. Krug, R. Freudinger, S. Mildenberger, K. Voelker, and M. Gekle Aldosterone-induced EGFR expression: interaction between the human mineralocorticoid receptor and the human EGFR promoter Am J Physiol Endocrinol Metab 292 6 Jun 2007 E1790 E1800
74. L. Miró, A. Pérez-Bosque, M. Maijó, C. Amat, R.J. Naftalin, and M. Moretó Aldosterone induces myofibroblast EGF secretion to regulate epithelial colonic permeability Am J Physiol Cell Physiol 304 9 May 1 2013 C918 C926
75. V.C. De Giusti, M.B. Nolly, and A.M. Yeves Aldosterone stimulates the cardiac Na(+)/H(+) exchanger via transactivation of the epidermal growth factor receptor Hypertension 58 5 Nov 2011 912 919
76. S. Sundar, and P.D. Dickinson Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate BMJ Case Rep Feb 25 2012 10.1136/bcr.11.2011.5238
77. R. Panet, M. Eliash, and H. Atlan Na +/K +/Cl- cotransporter activates MAP-kinase cascade downstream to protein kinase C, and upstream to MEK J Cell Physiol 206 3 Mar 2006 578 585
78. S.A. Francis, S. Cheng, C.L. Arteaga, and J. Moslehi Heart failure and breast cancer therapies: moving towards personalized risk assessment J Am Heart Assoc 3 1 Feb 28 2014 e000780